Log in

NASDAQ:ALLOAllogene Therapeutics Stock Price, Forecast & News

$42.63
-0.37 (-0.86 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$41.84
Now: $42.63
$45.88
50-Day Range
$25.67
MA: $37.55
$54.04
52-Week Range
$17.43
Now: $42.63
$55.00
Volume1.45 million shs
Average Volume2.05 million shs
Market Capitalization$5.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLO
CUSIPN/A
CIKN/A
Phone650-457-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.16 per share

Profitability

Net Income$-184,590,000.00

Miscellaneous

Employees122
Market Cap$5.34 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

How has Allogene Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALLO shares have increased by 70.2% and is now trading at $42.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allogene Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allogene Therapeutics.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics Inc (NASDAQ:ALLO) released its earnings results on Wednesday, May, 6th. The company reported ($0.58) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.58). View Allogene Therapeutics' earnings history.

What price target have analysts set for ALLO?

16 brokers have issued 1-year price targets for Allogene Therapeutics' shares. Their forecasts range from $27.00 to $70.00. On average, they anticipate Allogene Therapeutics' share price to reach $46.15 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price. View analysts' price targets for Allogene Therapeutics.

Has Allogene Therapeutics been receiving favorable news coverage?

Press coverage about ALLO stock has been trending somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allogene Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAllogene Therapeutics.

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 13,170,000 shares, a drop of 6.7% from the April 30th total of 14,110,000 shares. Based on an average trading volume of 758,900 shares, the days-to-cover ratio is presently 17.4 days. Currently, 26.0% of the company's stock are short sold. View Allogene Therapeutics' Current Options Chain.

Who are some of Allogene Therapeutics' key competitors?

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Teladoc Health (TDOC), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), bluebird bio (BLUE) and Sorrento Therapeutics (SRNE).

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)
  • Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52)

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (7.16%), BlackRock Inc. (3.91%), Capital International Investors (3.65%), VV Manager LLC (1.83%), Alliancebernstein L.P. (1.58%) and State Street Corp (1.35%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt and Group Holdings (Sbs) Advis Tpg. View institutional ownership trends for Allogene Therapeutics.

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including VV Manager LLC, BlackRock Inc., Russell Investments Group Ltd., Morgan Stanley, Coastal Bridge Advisors LLC, Shikiar Asset Management Inc., Deutsche Bank AG, and Victory Capital Management Inc.. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, and Group Holdings (Sbs) Advis Tpg. View insider buying and selling activity for Allogene Therapeutics.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, Casdin Capital LLC, Rock Springs Capital Management LP, Eaton Vance Management, Alliancebernstein L.P., Tekla Capital Management LLC, and Wildcat Capital Management LLC. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang, and Group Holdings (Sbs) Advis Tpg. View insider buying and selling activity for Allogene Therapeutics.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $42.63.

How big of a company is Allogene Therapeutics?

Allogene Therapeutics has a market capitalization of $5.34 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.